Kailera Therapeutics, Inc. Common Stock reports a Return on Equity (ROE) of 22.41%.

What is KLRA's dividend yield?

Kailera Therapeutics, Inc. Common Stock offers a dividend yield of 0.00%.

What is KLRA's Quality Score?

Our AI rates KLRA's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy KLRA?

Our AI Timing Score for KLRA is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does KLRA belong to?

Kailera Therapeutics, Inc. Common Stock is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Kailera Therapeutics, Inc. (KLRA) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

KLRA AI Analysis Summary

Our AI summary for KLRA: Kailera Therapeutics, Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 22.41%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

KLRA

Kailera Therapeutics, Inc. Common Stock

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 18.11

0.79 (4.56%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

22.4%

ROE

-15.5%

ROA

0.00%

Div Yield

KAILERA THERAPEUTICS, INC. COMMON STOCK
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 18.11 Price 0.79 (4.56%) Day Change	NEWS SCORE: N/A

KLRA, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

41%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	18.11
PBV / Sector	-5.19 / 44,022.72
Earning Per Share	-0.78

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	9.22 M
Average 1W Daily Value	7.77 M

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.24
NPM Average (%) / Sector	0.03 / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-15.50 / 185,260.96
ROA Average (%) / Sector	-12.30 / 36,684.70
ROA Change Average (%) / Sector	-9,076.77 / 422,221.66
ROE (%) / Sector	22.41 / 243,762.23 GOOD
ROE Average (%) / Sector	21.37 / 48,758.47 GOOD
ROE Change Average (%) / Sector	-21,533.14 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:26
Symbol	KLRA
Name	KAILERA THERAPEUTICS, INC. COMMON STOCK
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	129.57 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	2,244.08 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 180 Third Avenue, Waltham, MA, United States, 02451

Phone: 781 317 0290

Website: https://www.kailera.com

Employees: 145

Sector: Healthcare >> Biotechnology

Description: Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.